BIOC - Biocept, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.0100
+0.0100 (+1.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.0000
Open1.0000
Bid1.01 x 36200
Ask1.02 x 1300
Day's Range0.9900 - 1.0400
52 Week Range0.6600 - 12.3000
Volume849,565
Avg. Volume2,319,939
Market Cap12.179M
Beta (3Y Monthly)3.59
PE Ratio (TTM)N/A
EPS (TTM)-12.40
Earnings DateMar 26, 2019 - Apr 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.13
Trade prices are not sourced from all markets
  • What Makes Biocept (BIOC) a New Buy Stock
    Zacks3 days ago

    What Makes Biocept (BIOC) a New Buy Stock

    Biocept (BIOC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • Biocept Announces Pricing of $7.5 Million Underwritten Public Offering
    PR Newswire8 days ago

    Biocept Announces Pricing of $7.5 Million Underwritten Public Offering

    SAN DIEGO, Feb. 8, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock and warrants to purchase up to 6,250,000 shares of the Company's common stock.  Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined price to the public of $1.20 per share and warrant.  Gross proceeds, before underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $7.5 million.

  • Biocept Announces Agreement with Agiomix FZ-LLC for Target Selector Liquid Biopsy Kits
    PR Newswire9 days ago

    Biocept Announces Agreement with Agiomix FZ-LLC for Target Selector Liquid Biopsy Kits

    SAN DIEGO, Feb. 7, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy solutions, announces that it has entered into an agreement with Agiomix FZ-LLC ("Agiomix"), a provider of genomics sample and bioinformatics services to customers around the world for both research and clinical applications. Under the agreement, Agiomix plans to validate Biocept's patented and proprietary liquid biopsy technology in order to perform testing for the detection of tumor biomarkers.

  • Published Case Series Indicates the Ability of Biocept's Liquid Biopsy Testing to Identify Actionable Biomarkers When Tissue Biopsy Is Unsuccessful
    PR Newswire11 days ago

    Published Case Series Indicates the Ability of Biocept's Liquid Biopsy Testing to Identify Actionable Biomarkers When Tissue Biopsy Is Unsuccessful

    SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of a peer-reviewed article featuring a case series of three patients indicating the clinical utility of Biocept's Target Selector™ circulating tumor DNA (ctDNA) testing in the management of patients with advanced non-small cell lung cancer (NSCLC). In each of the three patient cases, Biocept's liquid biopsy testing detected activating EGFR mutations where tissue biopsy was inadequate, and targeted EGFR-directed therapy was subsequently administered.

  • ACCESSWIRE17 days ago

    Biocept, Inc., Pipeline Review, Upcoming Catalysts and Milestones

    NEW YORK, NY / ACCESSWIRE / January 30, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Biocept, Inc. (BIOC), a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. Biocept is an emerging player in the liquid biopsy space and the key for Biocept is to continue to raise awareness about its technology platform.

  • Biocept Launches Liquid Biopsy Kits Intended to Broaden Use of its Proprietary Technology Platform for High Sensitivity Detection of Circulating Tumor DNA
    PR Newswire19 days ago

    Biocept Launches Liquid Biopsy Kits Intended to Broaden Use of its Proprietary Technology Platform for High Sensitivity Detection of Circulating Tumor DNA

    SAN DIEGO, Jan. 28, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of research-use-only (RUO) kits, which are intended to enable molecular laboratories around the world to utilize Biocept's Target Selector™ circulating tumor DNA (ctDNA) assays to perform liquid biopsy testing.  Biocept's Target Selector™ platform is patent protected in the United States and in 10 major international territories. The first available kit is for the high-sensitivity detection of EGFR oncogene mutations, which are among the most frequently evaluated biomarkers for lung cancer.

  • Should You Worry About Biocept, Inc.’s (NASDAQ:BIOC) CEO Salary Level?
    Simply Wall St.25 days ago

    Should You Worry About Biocept, Inc.’s (NASDAQ:BIOC) CEO Salary Level?

    Mike Nall has been the CEO of Biocept, Inc. (NASDAQ:BIOC) since 2013. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll Read More...

  • Biocept Announces Pricing of $2.2 Million Registered Direct Offering
    PR Newswire29 days ago

    Biocept Announces Pricing of $2.2 Million Registered Direct Offering

    SAN DIEGO, Jan. 18, 2019 /PRNewswire/ -- Biocept, Inc. (BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $2.2 million of its common stock in a registered direct offering. The purchase price for one share of common stock will be $2.25. Under the terms of the purchase agreement, Biocept has agreed to sell approximately 990,000 shares of its common stock.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Adamis Pharmaceuticals and Biocept

    NEW YORK, NY / ACCESSWIRE / January 17, 2019 / Despite concerns of a partial government shutdown, U.S. markets extended gains for the second consecutive session on Wednesday on strong earnings from Bank ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Biogen and Biocept

    NEW YORK, NY / ACCESSWIRE / December 19, 2018 / Shares of Biogen were continuing to slump on Tuesday after a slight recovery on Monday from last week’s descent. The company and Alkermes plc recently announced that Alkermes has submitted a New Drug Application to the FDA for diroximel fumarate (BIIB098). Shares of Biocept were soaring on high volume on news that the company has entered into a Software License and Laboratory Data Supply Agreement with Prognos, Inc.

  • Biocept and Prognos Enter Into Partnership to Apply Artificial Intelligence in Order to Help Pharmaceutical and Life Sciences Companies Optimize Commercialization of Biomarker-Targeted Therapies in Oncology
    PR Newswire2 months ago

    Biocept and Prognos Enter Into Partnership to Apply Artificial Intelligence in Order to Help Pharmaceutical and Life Sciences Companies Optimize Commercialization of Biomarker-Targeted Therapies in Oncology

    SAN DIEGO, Dec. 18, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, has entered into a Software License and Laboratory Data Supply Agreement with Prognos, Inc., an innovator in predicting disease by applying artificial intelligence (AI) to clinical laboratory diagnostics. Under the agreement, Biocept will supply de-identified data from its liquid biopsy testing to Prognos, which will leverage its AI capabilities to help its pharmaceutical clients ensure that the right patients receive the right therapies.

  • Benzinga3 months ago

    The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 28) Merck & Co., Inc. (NYSE: MRK ) Ionis Pharmaceuticals ...

  • What Kind Of Shareholder Appears On The Biocept Inc’s (NASDAQ:BIOC) Shareholder Register?
    Simply Wall St.3 months ago

    What Kind Of Shareholder Appears On The Biocept Inc’s (NASDAQ:BIOC) Shareholder Register?

    If you want to know who really controls Biocept Inc (NASDAQ:BIOC), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock in bigger Read More...

  • Biocept Reports Third Quarter 2018 Financial Results
    PR Newswire3 months ago

    Biocept Reports Third Quarter 2018 Financial Results

    Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , Nov. 13, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to ...

  • Biocept to Release Third Quarter 2018 Financial Results and Host Investor Conference Call on November 13, 2018
    PR Newswire3 months ago

    Biocept to Release Third Quarter 2018 Financial Results and Host Investor Conference Call on November 13, 2018

    SAN DIEGO , Nov. 6, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable ...

  • Biocept Announces New Executive Hires to its Sales and Marketing Organization
    PR Newswire3 months ago

    Biocept Announces New Executive Hires to its Sales and Marketing Organization

    SAN DIEGO, Nov. 5, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the appointments of Scott Nicholson as Vice President of  Sales - US and Cory Dunn as Vice President of Marketing. Nicholson has 24 years of experience in the medical laboratory industry with a focus in oncology for the physician and hospital markets, and Dunn has over 15 years of commercial marketing experience in the life sciences industry, specializing in diagnostic testing services for oncology. "I am pleased to announce the hiring of Cory and Scott, as we restructure and refocus the sales and marketing organization at Biocept," said Edwin Hendrick, Senior Vice President, Chief Commercial Officer at Biocept.

  • Biocept (BIOC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks4 months ago

    Biocept (BIOC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Biocept (BIOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Biocept to Present at the Dawson James Securities Small Cap Growth Conference on October 30
    PR Newswire4 months ago

    Biocept to Present at the Dawson James Securities Small Cap Growth Conference on October 30

    SAN DIEGO , Oct. 23, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve ...

  • Biocept Obtains Japanese Patent for its Target Selector Oncogene Mutation Enrichment and Detection Platform
    PR Newswire4 months ago

    Biocept Obtains Japanese Patent for its Target Selector Oncogene Mutation Enrichment and Detection Platform

    The patent provides intellectual property protection for the Company's Switch-Blocker technology which is core to Biocept's Target Selector™ assays for analysis using real-time PCR, Sanger sequencing and next-generation sequencing.

  • Biocept to Present at The MicroCap Conference in New York on October 2
    PR Newswire5 months ago

    Biocept to Present at The MicroCap Conference in New York on October 2

    SAN DIEGO , Sept. 25, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to ...

  • Biocept Awarded Patent in Hong Kong for its Target Selector Platform Using Antibodies and a Microchannel to Perform Liquid Biopsy
    PR Newswire5 months ago

    Biocept Awarded Patent in Hong Kong for its Target Selector Platform Using Antibodies and a Microchannel to Perform Liquid Biopsy

    The issued patent covers the use of antibodies for the capture of any cell of interest, including circulating tumor cells (CTCs), within a microchannel. "The granting of this patent further expands globally Biocept's intellectual property protection for capturing and detecting any cell of interest," said Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept.

  • Biocept Announces Pricing of $2.5 Million Registered Direct Offering Priced at Market
    PR Newswire5 months ago

    Biocept Announces Pricing of $2.5 Million Registered Direct Offering Priced at Market

    SAN DIEGO, Sept. 21, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC) ("Biocept" or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $2.5 million of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in a registered direct offering and concurrent private placement at market. The combined purchase price for one share of common stock (or one pre-funded warrant to purchase common stock in lieu thereof) and each warrant will be priced at $3.285.

  • Biocept Names Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer
    PR Newswire5 months ago

    Biocept Names Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer

    SAN DIEGO, Sept. 10, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the appointment of Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer. Mr. Hendrick brings to Biocept over 25 years of sales and commercial leadership experience in the healthcare industry, with recent senior level commercial and operational positions in the clinical diagnostics segment. "Edwin's outstanding experience developing successful commercial organizations in early-stage companies is a natural fit for Biocept, as we aim to continue to build our market presence in the emerging liquid biopsy segment," said Michael Nall, President and Chief Executive Officer of Biocept.

  • Biocept's Target Selector Platform Featured in Two Poster Presentations at the IASLC 19th World Conference on Lung Cancer
    PR Newswire5 months ago

    Biocept's Target Selector Platform Featured in Two Poster Presentations at the IASLC 19th World Conference on Lung Cancer

    SAN DIEGO, Sept. 6, 2018 /PRNewswire/ -- Biocept, Inc. (BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that two poster presentations featuring clinical data sets using its Target Selector™ liquid biopsy platform will be presented at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer. The conference is being held September 23-26, 2018 in Toronto at the Metro Toronto Convention Centre.

  • Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer
    PR Newswire6 months ago

    Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer

    Allegheny Health Network's Cancer Institute spearheading the evaluation PITTSBURGH and SAN DIEGO , Aug. 23, 2018 /PRNewswire/ -- Highmark Health announced today that through its VITAL Innovation Program, ...